| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Mark Robson | Q51026477 |
| P2093 | author name string | Elizabeth A Comen | |
| P2860 | cites work | DNA Damage, Aging, and Cancer | Q22121931 |
| High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs | Q24644255 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| Genome maintenance mechanisms for preventing cancer | Q28131737 | ||
| Regulation of DNA double-strand break repair pathway choice | Q28262730 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| Cisplatin: mode of cytotoxic action and molecular basis of resistance | Q29615385 | ||
| Poly(ADP-ribose): novel functions for an old molecule | Q29617735 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors | Q33896961 | ||
| Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens | Q33915724 | ||
| Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme | Q33971109 | ||
| Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. | Q34017159 | ||
| Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas | Q34492521 | ||
| Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies | Q34550979 | ||
| Toward specific functions of poly(ADP-ribose) polymerase-2. | Q34763353 | ||
| Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse | Q35018839 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors | Q36111918 | ||
| Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors | Q36426742 | ||
| Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells | Q36654891 | ||
| Mammalian single-strand break repair: mechanisms and links with chromatin | Q36659772 | ||
| A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification | Q36751371 | ||
| Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation | Q36842905 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| Modeling therapy resistance in genetically engineered mouse cancer models | Q37047414 | ||
| Poly(ADP-ribose) polymerase: a new therapeutic target? | Q37149802 | ||
| Poly ADP-ribose polymerase-1: an international molecule of mystery | Q37158860 | ||
| A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair | Q37203855 | ||
| Triple-negative breast cancer: risk factors to potential targets | Q37352430 | ||
| Synthetic lethality: a framework for the development of wiser cancer therapeutics | Q37442913 | ||
| A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor | Q38279200 | ||
| Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. | Q39971672 | ||
| BRCA1 dysfunction in sporadic basal-like breast cancer | Q42502209 | ||
| Expression of BRCA1 protein in breast cancer and its prognostic significance | Q42526565 | ||
| Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura | Q42969471 | ||
| Targeting the molecular defect in BRCA-deficient tumors for cancer therapy. | Q45914279 | ||
| A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity | Q63383824 | ||
| The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin | Q64388522 | ||
| Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics | Q77340263 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 48-52 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | The Cancer Journal | Q2589130 |
| P1476 | title | Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer | |
| P478 | volume | 16 |
| Q34636501 | 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma |
| Q36432567 | A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer |
| Q100660457 | ARe we there yet? Understanding androgen receptor signaling in breast cancer |
| Q85204799 | Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up) |
| Q35889626 | Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67. |
| Q41455102 | Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results |
| Q35201664 | DNA damage and breast cancer |
| Q37292020 | Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint |
| Q34664112 | Helicobacter pylori activation of PARP-1: usurping a versatile regulator of host cellular health |
| Q37995507 | Hereditary breast cancer: practical pursuit for clinical translation |
| Q39034710 | INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells |
| Q92409051 | Mild antagonistic effect of Valproic acid in combination with AZD2461 in MCF-7 breast cancer cells |
| Q34460831 | Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer |
| Q61796965 | NADP is an endogenous PARP inhibitor in DNA damage response and tumor suppression |
| Q92623697 | PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation |
| Q33631833 | Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma |
| Q36284245 | Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis |
| Q28072755 | Recent developments and translational aspects in targeted therapy for metastatic breast cancer |
| Q27025648 | Small-molecule inhibitors of the Myc oncoprotein |
| Q46493806 | Sonographic features of triple-negative and non-triple-negative breast cancer |
| Q49852384 | Sustained Release Talazoparib Implants for Localized Treatment of BRCA1-deficient Breast Cancer |
| Q37223362 | Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase |
| Q34204660 | Targeting poly(ADP-ribose) polymerase activity for cancer therapy |
| Q28552519 | The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study |
| Q38004606 | Triple-negative breast cancer: making the most of a misnomer |
| Q39633140 | Twelve cases of metaplastic carcinoma of the breast: experience of the university hospital of Fez Morocco |
Search more.